Linda K. Buckett - Concepedia

Author

Linda K. Buckett

AstraZeneca (United Kingdom)

Also Known As

Buckett, Linda K., L Buckett, L. Buckett, Linda Buckett, Linda K Buckett, Linda K. Buckett

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (Sweden)Columbia University AstraZeneca (Singapore)AstraZeneca (United States)

About

Linda K. Buckett is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	956
2	Biochemistry	10	10	925
3	Natural Sciences	7	7	768
4	Cell Biology	2	2	187
5	Health Sciences	1	1	15

Linda K. Buckett

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca. Fergus McTaggart, Linda K. Buckett, Robert G. Davidson, The American Journal of Cardiology Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceOxysterolBiochemistry	2001	412
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson, Science Translational Medicine	2017	175
Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and <i>de novo</i> synthesized fatty acids in HepG2 cells Haja Wurie, Linda K. Buckett, Victor A. Zammit FEBS Journal GlycobiologyBiosynthesisIntracellular LipolysisFatty AcidsMetabolism	2012	119
DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Alan M. Birch, Linda K. Buckett, Andrew V. Turnbull PubMed ObesityMetabolic SyndromeMolecular PharmacologyGene DeletionDiabetes Management	2010	85
DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle Li Liu, Shuiqing Yu, Raffay Khan, Journal of Lipid Research	2011	78
Discovery of a Potent, Selective, and Orally Efficacious Pyrimidinooxazinyl Bicyclooctaneacetic Acid Diacylglycerol Acyltransferase-1 Inhibitor Alan M. Birch, Susan Birtles, Linda K. Buckett, Journal of Medicinal Chemistry Bicyclooctaneacetic Acid DerivativePharmacotherapyChemical BiologyExperimental PharmacologyTranslational Pharmacology	2009	75
Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying Gene P. Ables, Kryscilla Jian Zhang Yang, Silke Vogel, Journal of Lipid Research	2012	72
Evidence That Diacylglycerol Acyltransferase 1 (DGAT1) Has Dual Membrane Topology in the Endoplasmic Reticulum of HepG2 Cells Haja Wurie, Linda K. Buckett, Victor A. Zammit Journal of Biological Chemistry Oligomeric Enzyme Dgat1GlycobiologyMolecular BiologyLipid MovementChemical Biology	2011	68
Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells Linda K. Buckett, Peter Ballard, Robert G. Davidson, Atherosclerosis OxysterolBiochemistryMedicineLiver PhysiologyLipid Peroxidation	2000	57
Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes William McCoull, Matthew S. Addie, Alan M. Birch, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryOxadiazole Dgat-1 InhibitorsBiochemistryVivo EvaluationNatural Sciences	2012	44

Page 1